Bortezomib dosing in relapsed multiple myeloma

Clin Lymphoma Myeloma. 2006 Sep;7(2):101-2. doi: 10.3816/CLM.2006.n.045.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Boronic Acids / administration & dosage*
  • Boronic Acids / adverse effects
  • Bortezomib
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Methylprednisolone / administration & dosage
  • Methylprednisolone / adverse effects
  • Middle Aged
  • Multiple Myeloma / complications
  • Multiple Myeloma / mortality
  • Multiple Myeloma / therapy*
  • Pyrazines / administration & dosage*
  • Pyrazines / adverse effects
  • Recurrence
  • Stem Cell Transplantation* / adverse effects
  • Stem Cell Transplantation* / methods
  • Stem Cell Transplantation* / mortality
  • Survival Rate

Substances

  • Boronic Acids
  • Pyrazines
  • Bortezomib
  • Methylprednisolone